FindTrial
Sign In

H3B-6545

DRUG2 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

Breast AdenocarcinomaBreast CancerBreast Cancer FemaleBreast NeoplasmsCancer, BreastER PositiveEstrogen Receptor Positive TumorEstrogen-receptor Positive Breast Cancer

Phase 1

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
CompletedNCT03250676
Eisai Inc.Breast Adenocarcinoma, Breast Cancer, Breast Cancer Female +5
Start: 2017-08-23End: 2023-10-26Updated: 2025-02-25
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
CompletedNCT04568902
Eisai Co., Ltd.Breast Neoplasms
Start: 2020-09-30End: 2025-10-01Updated: 2025-10-23

Related Papers

Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer.
2025-06-132 citations
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Journal of Clinical Oncology2024-06-014 citations
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Molecular Cancer Therapeutics2022-03-3128 citations
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
Journal of Clinical Oncology2021-05-2037 citations
Abstract PS12-23: Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer
Cancer Research2021-02-153 citations
Abstract PS12-15: Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2- BC)
Cancer Research2021-02-151 citations
Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).
Journal of Clinical Oncology2019-05-2010 citations
Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.
Journal of Clinical Oncology2019-05-20